This segment focuses on the research, development, and commercialization of novel immunotherapies for various cancers. Key activities include clinical trials for agents like ANKTIVA (nogapendekin alfa inbakicept-pmln) in bladder cancer and other solid tumors. The segment utilizes platforms such as antibody cytokine fusion proteins and natural killer cell therapies. Patient impact is addressed through the potential for improved survival rates and quality of life. Market positioning is enhanced by the first-in-class IL-15 agonist immunotherapy, ANKTIVA. Future opportunities include expanding the use of ANKTIVA and other therapies into additional cancer indications. Regulatory aspects involve FDA approvals and ongoing clinical studies. Partnerships with BeiGene and others support clinical development and market access.

This segment is dedicated to developing vaccines and therapies for infectious diseases, including SARS-CoV-2 and HIV. Research and development efforts focus on vaccine technologies and synthetic immunomodulators. The segment leverages its expertise in immunology to create treatments that stimulate the body's immune response. Patient impact is significant, as these therapies aim to prevent and treat life-threatening infections. Market positioning is driven by the need for effective treatments against emerging and existing pathogens. Future opportunities include expanding the pipeline of vaccine candidates and exploring new therapeutic approaches. Regulatory aspects involve obtaining approvals from health authorities for vaccines and therapies. Collaborations with research institutions and pharmaceutical companies are crucial for advancing these programs.